Ausdal Financial Partners Inc. Purchases 10,262 Shares of Pfizer Inc. (NYSE:PFE)

Ausdal Financial Partners Inc. raised its position in Pfizer Inc. (NYSE:PFE) by 66.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,658 shares of the biopharmaceutical company’s stock after acquiring an additional 10,262 shares during the period. Ausdal Financial Partners Inc.’s holdings in Pfizer were worth $681,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of PFE. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the 4th quarter worth $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the fourth quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Pfizer in the 4th quarter valued at approximately $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer in the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC purchased a new stake in Pfizer during the 4th quarter worth approximately $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently commented on PFE. UBS Group lowered their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Citigroup decreased their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Truist Financial cut their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Bank of America reaffirmed a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Down 0.6 %

Shares of NYSE:PFE opened at $25.05 on Friday. The business has a fifty day moving average of $26.09 and a two-hundred day moving average of $26.97. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $142.08 billion, a P/E ratio of 17.77, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the prior year, the firm posted $0.10 earnings per share. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.